title: Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates.
abstract: The ABC protein P-glycoprotein (Pgp or ABCB1) is a multidrug efflux pump capable of transporting many structurally diverse substrates from within the lipid bilayer. Previous studies have demonstrated the importance of the membrane in modulating Pgp function, but few have quantified these effects. We employed purified Pgp reconstituted into phospholipid bilayers with defined gel to liquid-crystalline melting transitions to investigate the effect of membrane environment on the transporter and three of its substrates. Equilibrium dialysis measurements indicated that Hoechst 33342, LDS-751, and MK-571 partitioned much more readily into liquid-crystalline phase bilayers than into gel phase bilayers. However, drug binding affinities revealed that Pgp bound the three substrates more tightly when the lipid bilayer was in the gel phase. The binding affinity of the transporter for substrates within the bilayer was low, in the millimolar range, suggesting that it interacts with them weakly. Thermodynamic analysis revealed that both drug-Pgp and drug-lipid interactions contribute to binding affinity. The kinetics of LDS-751 and Hoechst 33342 transport by reconstituted Pgp was monitored using a real-time fluorescence-based assay to obtain apparent turnover frequencies. Transport rates were found to be sensitive to both drug structure and lipid environment. Arrhenius and transition state analysis of transport rates suggested that the rate of drug transport depends on both the affinity of Pgp for substrate and protein conformational changes. Transport rates did not appear to be limited exclusively by the rate of ATP hydrolysis and may be partially controlled by the rate of drug dissociation.
authors.affiliation: Department of Molecular and Cellular Biology and Biophysics Interdepartmental Group, University of Guelph, Guelph, Ontario, Canada N1G 2W1.
authors.forename: Adam T
authors.initials: AT
authors.lastname: Clay
authors.forename: Frances J
authors.initials: FJ
authors.lastname: Sharom
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism*; D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D001562:Benzimidazoles / Q000378:metabolism / Q000493:pharmacokinetics; D001693:Biological Transport, Active; D002460:Cell Line; D006224:Cricetinae; D005456:Fluorescent Dyes / Q000378:metabolism / Q000493:pharmacokinetics*; D006868:Hydrolysis; D020024:Leukotriene Antagonists / Q000378:metabolism / Q000493:pharmacokinetics*; D008051:Lipid Bilayers / Q000737:chemistry / Q000378:metabolism*; D009930:Organic Chemicals / Q000378:metabolism / Q000493:pharmacokinetics; D010743:Phospholipids / Q000737:chemistry / Q000378:metabolism; D011422:Propionates / Q000378:metabolism / Q000493:pharmacokinetics*; D011485:Protein Binding; D011804:Quinolines / Q000378:metabolism / Q000493:pharmacokinetics*; D013816:Thermodynamics
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D001562:Benzimidazoles; D005456:Fluorescent Dyes; D020024:Leukotriene Antagonists; D008051:Lipid Bilayers; D009930:Organic Chemicals; D010743:Phospholipids; D011422:Propionates; D011804:Quinolines; C057718:6-(Dimethylamino)-2-((1E,3E)-4-(4-(dimethylamino)phenyl)-1,3-butadien-1-yl)-1-ethylquinolinium perchlorate; C059141:verlukast; D000251:Adenosine Triphosphatases; C017807:bisbenzimide ethoxide trihydrochloride